{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T12:02:22Z","timestamp":1790337742786,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological and Toxicological Methods"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.vascn.2026.108564","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T15:06:11Z","timestamp":1784559971000},"page":"108564","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Predicting thorough QT safety profile using hERG IC10 versus IC50"],"prefix":"10.1016","volume":"140","author":[{"given":"Andrew G.","family":"Edwards","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"William J.","family":"Crumb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vascn.2026.108564_bb0005","series-title":"ICH E14\/S7B Implementation working group clinical and nonclinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential questions and answers E14\/S7B Q&As","author":"Anonymous","year":"2022"},{"key":"10.1016\/j.vascn.2026.108564_bb0010","series-title":"Training materials examples for ICH E14 Q&A 5.1 Table 1. Integrated risk assessment","author":"Anonymous","year":"2022"},{"key":"10.1016\/j.vascn.2026.108564_bb0015","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1113\/JP275733","article-title":"Sinusoidal voltage protocols for rapid characterisation of ion channel kinetics","volume":"596","author":"Beattie","year":"2018","journal-title":"The Journal of Physiology"},{"key":"10.1016\/j.vascn.2026.108564_bb0020","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.vascn.2016.05.012","article-title":"Comprehensive in vitro Proarrhythmia assay (CiPA): Pending issues for successful validation and implementation","volume":"81","author":"Cavero","year":"2016","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2026.108564_bb0025","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1517\/14740338.2014.915311","article-title":"Comprehensive in vitro Proarrhythmia assay, a novel in vitro\/in silico paradigm to detect ventricular proarrhythmic liability: A visionary 21st century initiative","volume":"13","author":"Cavero","year":"2014","journal-title":"Expert Opinion on Drug Safety"},{"key":"10.1016\/j.vascn.2026.108564_bb0030","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.vascn.2015.06.004","article-title":"CiPA: Ongoing testing, future qualification procedures, and pending issues","volume":"76","author":"Cavero","year":"2015","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2026.108564_bb0035","first-page":"15","article-title":"The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative \u2014 Update on progress","volume":"81","author":"Colatsky","year":"2016","journal-title":"Journal of Pharmacology and Toxicology"},{"key":"10.1016\/j.vascn.2026.108564_bb0040","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1161\/01.RES.77.5.950","article-title":"Description of a nonselective cation current in human atrium","volume":"77","author":"Crumb","year":"1995","journal-title":"Circulation Research"},{"key":"10.1016\/j.vascn.2026.108564_bb0045","first-page":"251","article-title":"An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel","volume":"81","author":"Crumb","year":"2016","journal-title":"Journal of Pharmacology and Toxicology"},{"key":"10.1016\/j.vascn.2026.108564_bb0050","doi-asserted-by":"crossref","first-page":"iv23","DOI":"10.1093\/europace\/eum168","article-title":"Detection and reporting of drug-induced proarrhythmias: Room for improvement","volume":"9","author":"Darpo","year":"2007","journal-title":"Europace"},{"key":"10.1016\/j.vascn.2026.108564_bb0055","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1476-5381.2009.00487.x","article-title":"The thorough QT\/QTc study 4 years after the implementation of the ICH E14 guidance","volume":"159","author":"Darpo","year":"2010","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.vascn.2026.108564_bb0060","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1002\/jcph.2309","article-title":"The new S7B\/E14 Q&a Document Provides Additional Opportunities to replace the thorough QT study","volume":"63","author":"Darpo","year":"2023","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1016\/j.vascn.2026.108564_bb0065","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2307\/2531595","article-title":"Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach","volume":"44","author":"DeLong","year":"1988","journal-title":"Biometrics"},{"key":"10.1016\/j.vascn.2026.108564_bb0070","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1002\/sim.5328","article-title":"Misuse of DeLong test to compare AUCs for nested models","volume":"31","author":"Demler","year":"2012","journal-title":"Statistics in Medicine"},{"key":"10.1016\/j.vascn.2026.108564_bb0075","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/bcp.13123","article-title":"Translating QT interval prolongation from conscious dogs to humans","volume":"83","author":"Dubois","year":"2017","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/j.vascn.2026.108564_bb0080","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3389\/fphys.2017.00616","article-title":"Optimization of an in silico cardiac cell model for Proarrhythmia risk assessment","volume":"8","author":"Dutta","year":"2017","journal-title":"Frontiers in Physiology"},{"key":"10.1016\/j.vascn.2026.108564_bb0085","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/(SICI)1097-0258(19960330)15:6<647::AID-SIM184>3.0.CO;2-P","article-title":"An asymptotic test for the equality of coefficients of variation from k populations","volume":"15","author":"Feltz","year":"1996","journal-title":"Statistics in Medicine"},{"key":"10.1016\/j.vascn.2026.108564_bb0090","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.pharmthera.2010.08.008","article-title":"An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation","volume":"129","author":"Gintant","year":"2011","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.vascn.2026.108564_bb0095","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.270","article-title":"Application of a systems pharmacology model for translational prediction of hERG-mediated QTc prolongation","volume":"4","author":"Gotta","year":"2016","journal-title":"Pharmacology Research & Perspectives"},{"key":"10.1016\/j.vascn.2026.108564_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2024.117135","article-title":"On the relationship between hERG inhibition and the magnitude of QTc prolongation: An in vitro to clinical translational analysis","volume":"492","author":"Harmer","year":"2024","journal-title":"Toxicology and Applied Pharmacology"},{"key":"10.1016\/j.vascn.2026.108564_bb0105","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.569489","article-title":"Identifying drug response by combining measurements of the membrane potential, the cytosolic calcium concentration, and the extracellular potential in microphysiological systems","volume":"11","author":"J\u00e6ger","year":"2021","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.vascn.2026.108564_bb0110","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.clpt.2005.02.004","article-title":"A pharmacokinetic-pharmacodynamic model for the quantitative prediction of Dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data","volume":"77","author":"Jonker","year":"2005","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.vascn.2026.108564_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2020.106871","article-title":"Drug-induced QT prolongation: Concordance of preclinical anesthetized canine model in relation to published clinical observations for ten CiPA drugs","volume":"103","author":"Koshman","year":"2020","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2026.108564_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.bpj.2019.07.030","article-title":"Rapid characterization of hERG channel kinetics II: Temperature dependence","author":"Lei","year":"2019","journal-title":"Biophysical Journal"},{"key":"10.1016\/j.vascn.2026.108564_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.bpj.2019.07.029","article-title":"Rapid characterization of hERG channel kinetics I: Using an automated high-throughput system","author":"Lei","year":"2019","journal-title":"Biophysical Journal"},{"key":"10.1016\/j.vascn.2026.108564_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2020.106900","article-title":"Revisiting the hERG safety margin after 20 years of routine hERG screening","volume":"105","author":"Leishman","year":"2020","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2026.108564_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2024.107524","article-title":"Supporting an integrated QTc risk assessment using the hERG margin distributions for three positive control agents derived from multiple laboratories and on multiple occasions","volume":"128","author":"Leishman","year":"2024","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2026.108564_bb0140","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.116.004628","article-title":"Improving the in silico assessment of Proarrhythmia risk by combining hERG (human ether-\u00e0-go-go-related gene) channel-drug binding kinetics and multichannel pharmacology","volume":"10","author":"Li","year":"2017","journal-title":"Circulation. Arrhythmia and Electrophysiology"},{"key":"10.1016\/j.vascn.2026.108564_bb0145","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/cpt.1184","article-title":"Assessment of an in silico mechanistic model for Proarrhythmia risk prediction under the CiPA initiative","volume":"105","author":"Li","year":"2019","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.vascn.2026.108564_bb0150","first-page":"318","article-title":"In silico pro-arrhythmia assessment: Can the results of the thorough QT study be predicted?","volume":"70","author":"Mirams","year":"2014","journal-title":"Journal of Pharmacology and Toxicology"},{"key":"10.1016\/j.vascn.2026.108564_bb0155","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.pbiomolbio.2015.12.002","article-title":"Variability in cardiac electrophysiology: Using experimentally-calibrated populations of models to move beyond the single virtual physiological human paradigm","volume":"120","author":"Muszkiewicz","year":"2016","journal-title":"Progress in Biophysics and Molecular Biology"},{"key":"10.1016\/j.vascn.2026.108564_bb0160","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.vascn.2013.03.007","article-title":"Translational pharmacokinetic\u2013pharmacodynamic modeling of QTc effects in dog and human","volume":"68","author":"Parkinson","year":"2013","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2026.108564_bb0165","first-page":"208","article-title":"In silico drug trials with virtual assay software predict drug cardiotoxicity and identify sub-populations at higher risk","volume":"88","author":"Passini","year":"2017","journal-title":"Journal of Pharmacology and Toxicology"},{"key":"10.1016\/j.vascn.2026.108564_bb0170","article-title":"Human in silico trials on drug-induced changes in electrophysiology and calcium dynamics using the virtual assay software","volume":"99","author":"Passini","year":"2018","journal-title":"Journal of Pharmacology and Toxicology"},{"key":"10.1016\/j.vascn.2026.108564_bb0175","doi-asserted-by":"crossref","first-page":"668","DOI":"10.3389\/fphys.2017.00668","article-title":"Human in silico drug trials demonstrate higher accuracy than animal models in predicting clinical pro-arrhythmic cardiotoxicity","volume":"8","author":"Passini","year":"2017","journal-title":"Frontiers in Physiology"},{"key":"10.1016\/j.vascn.2026.108564_bb0180","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1111\/bph.14786","article-title":"Drug-induced shortening of the electromechanical window is an effective biomarker for in silico prediction of clinical risk of arrhythmias","volume":"176","author":"Passini","year":"2019","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.vascn.2026.108564_bb0185","first-page":"209","article-title":"A novel in silico human cardiac Purkinje cell model to investigate drug safety and efficacy","volume":"88","author":"Passini","year":"2017","journal-title":"Journal of Pharmacology and Toxicology"},{"key":"10.1016\/j.vascn.2026.108564_bb0190","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/toxsci\/kfx125","article-title":"An analysis of the relationship between preclinical and clinical QT interval-related data","volume":"159","author":"Pollard","year":"2017","journal-title":"Toxicological Sciences"},{"key":"10.1016\/j.vascn.2026.108564_bb0195","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0008-6363(02)00846-5","article-title":"Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development","volume":"58","author":"Redfern","year":"2003","journal-title":"Cardiovascular Research"},{"key":"10.1016\/j.vascn.2026.108564_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2020.114961","article-title":"A systematic strategy for estimating hERG block potency and its implications in a new cardiac safety paradigm","volume":"394","author":"Ridder","year":"2020","journal-title":"Toxicology and Applied Pharmacology"},{"key":"10.1016\/j.vascn.2026.108564_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4062\/biomolther.2009.17.1.1","article-title":"Pre-clinical QT risk assessment in pharmaceutical companies - issues of current QT risk assessment","volume":"17","author":"Takasuna","year":"2009","journal-title":"Biomolecules & Therapeutics"},{"key":"10.1016\/j.vascn.2026.108564_bb0210","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.vascn.2009.05.002","article-title":"A HESI consortium approach to assess the human predictive value of non-clinical repolarization assays","volume":"60","author":"Trepakova","year":"2009","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2026.108564_bb0215","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/cpt.1303","article-title":"Assessment of multi-Ion Channel block in a phase I randomized study design: Results of the CiPA phase I ECG biomarker validation study","volume":"105","author":"Vicente","year":"2018","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.vascn.2026.108564_bb0220","first-page":"15","article-title":"CiPA challenges and opportunities from a non-clinical, clinical and regulatory perspectives. An overview of the safety pharmacology scientific discussion","volume":"93","author":"Wallis","year":"2018","journal-title":"Journal of Pharmacology and Toxicology"},{"key":"10.1016\/j.vascn.2026.108564_bb0225","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1476-5381.2009.00395.x","article-title":"Integrated risk assessment and predictive value to humans of non-clinical repolarization assays","volume":"159","author":"Wallis","year":"2010","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.vascn.2026.108564_bb0230","first-page":"116","article-title":"Towards a drug concentration effect relationship for QT prolongation and torsades de pointes","volume":"5","author":"Webster","year":"2002","journal-title":"Current Opinion in Drug Discovery & Development"},{"key":"10.1016\/j.vascn.2026.108564_bb0235","article-title":"Measuring kinetics and potency of hERG block for CiPA","volume":"87","author":"Windley","year":"2017","journal-title":"Journal of Pharmacology and Toxicology"},{"key":"10.1016\/j.vascn.2026.108564_bb0240","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.tcm.2017.07.010","article-title":"CredibleMeds.org: What does it offer?","volume":"28","author":"Woosley","year":"2018","journal-title":"Trends in Cardiovascular Medicine"},{"key":"10.1016\/j.vascn.2026.108564_bb0245","series-title":"QT drugs List","author":"Woosley","year":"2023"},{"key":"10.1016\/j.vascn.2026.108564_bb0250","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s40264-017-0519-0","article-title":"Adverse drug event causality analysis (ADECA): A process for evaluating evidence and assigning drugs to risk categories for sudden death","volume":"40","author":"Woosley","year":"2017","journal-title":"Drug Safety"},{"key":"10.1016\/j.vascn.2026.108564_bb0255","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.3389\/fphar.2019.01643","article-title":"Blinded in silico drug trial reveals the minimum set of ion channels for Torsades de pointes risk assessment","volume":"10","author":"Zhou","year":"2020","journal-title":"Frontiers in Pharmacology"}],"container-title":["Journal of Pharmacological and Toxicological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871926001577?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871926001577?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T11:22:44Z","timestamp":1790335364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056871926001577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":51,"alternative-id":["S1056871926001577"],"URL":"https:\/\/doi.org\/10.1016\/j.vascn.2026.108564","relation":{},"ISSN":["1056-8719"],"issn-type":[{"value":"1056-8719","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predicting thorough QT safety profile using hERG IC10 versus IC50","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological and Toxicological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vascn.2026.108564","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108564"}}